BioNTech to Present New Late-Stage Oncology Data at ESMO 2026, Including First ROSETTA Lung-107 Phase 2 Results for Pumitamig Plus Docetaxel
BioNTech to Present New Late-Stage Oncology Data at ESMO 2026, Including First ROSETTA Lung-107 Phase 2 Results for Pumitamig Plus Docetaxel Quiver Quantitative